AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24978834 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg·kg)
Number of subjects: 14
Study 24978834 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 14
Study 24978834 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Nitrate (0.45 g)
Number of subjects: 14
Study 24835757 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser peripheral iridotomy (LPI) in treated eyes
Number of subjects: 0
Study 24835757 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated fellow eyes)
Number of subjects: 0
Study 21562143 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GDP bicarbonate-lactate-buffered PD solutions (BL)
Number of subjects: 21
Study 21562143 — intervention group
Group type: COMPARATOR
Intervention: Classic glucose degradation product (GDP)-rich lactate-buffered PD solutions (L)
Number of subjects: 21
Study 19709326 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir/ritonavir or Lopinavir/ritonavir
Number of subjects: 115
Study 19709326 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Number of subjects: 115
Study 19709326 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring
Number of subjects: 115
Study 17069838 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiogram (ECG) analysis at baseline and annually thereafter
Number of subjects: 6595
Study 17069838 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiogram (ECG) analysis
Number of subjects: 6595
Study 17069838 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiogram (ECG) detection
Number of subjects: 6595
Study 15024661 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with lumbar disc herniation
Number of subjects: 103
Study 15024661 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 103
Study 15024661 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with successful model fit
Number of subjects: 103
Study 15024661 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with unsuccessful model fit
Number of subjects: 103
Study 12607793 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg once daily for 5 days
Number of subjects: 63
Study 12607793 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily for 5 days
Number of subjects: 63
Study 9803327 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain triglycerides (20% LCT)
Number of subjects: 21
Study 9803327 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides/long-chain triglycerides (20% MCT/LCT: 50/50)
Number of subjects: 21
Study 9803327 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride, NaCl)
Number of subjects: 21
Study 7647083 — intervention group
Group type: COMPARATOR
Intervention: Yohimbine 10.8 mg
Number of subjects: 10
Study 7647083 — intervention group
Group type: COMPARATOR
Intervention: Clonidine 200 micrograms
Number of subjects: 10
Study 7647083 — intervention group
Group type: COMPARATOR
Intervention: Clonidine 300 micrograms
Number of subjects: 10
Study 2696020 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg iron daily
Number of subjects: 458
Study 2696020 — intervention group
Group type: COMPARATOR
Intervention: No supplements
Number of subjects: 458
Study 2696020 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg iron daily
Number of subjects: 458
Study 2696020 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg or 120 mg iron daily
Number of subjects: 458
Study 2696020 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferritin iron administration
Number of subjects: 458
Study 326306 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclandelate treatment
Number of subjects: 22
Study 326306 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 22
Study 30658192 — intervention group
Group type: EXPERIMENTAL
Intervention: Camelina sativa oil (CSO) - 10 g of alpha-linolenic acid/day
Number of subjects: 88
Study 30658192 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty fish - 4 fish meals/week
Number of subjects: 88
Study 30658192 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean fish - 4 fish meals/week
Number of subjects: 88
Study 30658192 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study 29927180 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem + ACEI/ARB (sustained-release diltiazem 120 mg daily)
Number of subjects: 106
Study 29927180 — intervention group
Group type: COMPARATOR
Intervention: Placebo + ACEI/ARB
Number of subjects: 106
Study 25614148 — intervention group
Group type: EXPERIMENTAL
Intervention: GW870086 0.2%
Number of subjects: 25
Study 25614148 — intervention group
Group type: EXPERIMENTAL
Intervention: GW870086 2%
Number of subjects: 25
Study 25614148 — intervention group
Group type: COMPARATOR
Intervention: Comparator (not specified)
Number of subjects: 25
Study 25614148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 24105075 — intervention group
Group type: EXPERIMENTAL
Intervention: EZN-2208 monotherapy (9 mg/m² on days 1, 8, and 15 every 28 days for patients with KRAS-mutant tumors)
Number of subjects: 0
Study 24105075 — intervention group
Group type: EXPERIMENTAL
Intervention: EZN-2208 plus cetuximab (400 mg/m² loading dose on day 1 followed by 250 mg/m² weekly starting on day 8)
Number of subjects: 0
Study 24105075 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan (125 mg/m² on days 1 and 8 every 21 days) plus cetuximab (400 mg/m² loading dose on day 1 followed by 250 mg/m² weekly starting on day 8)
Number of subjects: 0
Study 24105075 — intervention group
Group type: EXPERIMENTAL
Intervention: EZN-2208 plus cetuximab
Number of subjects: 0
Study 24105075 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan plus cetuximab
Number of subjects: 0
Study 21666442 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-support ventilation at 9.6 cm H2O
Number of subjects: 16
Study 21666442 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-support ventilation at 14.9 cm H2O
Number of subjects: 16
Study 21666442 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-support ventilation increase by 5 cm H2O
Number of subjects: 16
Study 18295614 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV)
Number of subjects: 27
Study 18295614 — intervention group
Group type: COMPARATOR
Intervention: Conventional Physiotherapy (PT)
Number of subjects: 27
Study 17135989 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 0
Study 17135989 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 0
Study 17135989 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination Treatment (COMB)
Number of subjects: 0
Study 17135989 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 0
Study 14579879 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt L-Pop self-etching adhesive plus sealant
Number of subjects: 0
Study 14579879 — intervention group
Group type: COMPARATOR
Intervention: Sealant only after phosphoric acid etch (Control)
Number of subjects: 0
Study 11064971 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior stabilized tibial component
Number of subjects: 176
Study 11064971 — intervention group
Group type: COMPARATOR
Intervention: Deep-dish tibial polyethylene component (Genesis II)
Number of subjects: 176
Study 8618758 — intervention group
Group type: EXPERIMENTAL
Intervention: Lensectomy-vitrectomy procedures (n=72 eyes)
Number of subjects: 98
Study 8618758 — intervention group
Group type: COMPARATOR
Intervention: No lensectomy-vitrectomy procedures (n=56 eyes)
Number of subjects: 98
Study 1598875 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous enalapril (1.25 mg) administered to group II patients after exercise testing.
Number of subjects: 97
Study 1598875 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in group I patients.
Number of subjects: 97
Study 1598875 — intervention group
Group type: COMPARATOR
Intervention: Group II patients (symptomatic heart failure) without intervention during exercise testing.
Number of subjects: 97
Study 6692664 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine (0.5-4 micrograms/min)
Number of subjects: 14
Study 6692664 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine (0.5 micrograms/min) during noradrenaline infusions
Number of subjects: 14
Study 6692664 — intervention group
Group type: COMPARATOR
Intervention: Histamine with cimetidine and pyrilamine (mepyramine)
Number of subjects: 14
Study 6692664 — intervention group
Group type: EXPERIMENTAL
Intervention: Local injections of Na131I
Number of subjects: 14
Study 31902602 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum 25-hydroxyvitamin D (25(OH)D)
Number of subjects: 73799
Study 30932165 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous GBR with implant placement
Number of subjects: 13
Study 30932165 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed GBR followed by implant placement after 6 months
Number of subjects: 13
Study 30932165 — intervention group
Group type: EXPERIMENTAL
Intervention: Total gain utilizing novel biomaterials
Number of subjects: 13
Study 30231466 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut group (28-56 g/day)
Number of subjects: 356
Study 30231466 — intervention group
Group type: COMPARATOR
Intervention: Control group (abstained from walnuts)
Number of subjects: 356
Study 27012997 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Directed Interaction Training (CDIT)
Number of subjects: 14
Study 27012997 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 14
Study 24685389 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (3 hours of therapy per day)
Number of subjects: 141
Study 24685389 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous passive motion (CPM) device (2 hours daily throughout length of stay)
Number of subjects: 141
Study 22313287 — intervention group
Group type: EXPERIMENTAL
Intervention: Abortive verum acupuncture (VAa)
Number of subjects: 20
Study 22313287 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture (VAp)
Number of subjects: 20
Study 22313287 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine (VC)
Number of subjects: 20
Study 22313287 — intervention group
Group type: COMPARATOR
Intervention: Placebo interventions (PAa, PC)
Number of subjects: 20
Study 22313287 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control (NI)
Number of subjects: 20
Study 19917946 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative somatostatin and its analogues
Number of subjects: 0
Study 19917946 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreaticoenterostomy
Number of subjects: 0
Study 19917946 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreaticogastrostomy
Number of subjects: 0
Study 19917946 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreaticoenteric anastomosis
Number of subjects: 0
Study 17762452 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-filtration plasmapheresis (DFPP)
Number of subjects: 82
Study 17762452 — intervention group
Group type: COMPARATOR
Intervention: No double-filtration plasmapheresis (no-DFPP)
Number of subjects: 82
Study 15025887 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological coherence condition
Number of subjects: 26
Study 15025887 — intervention group
Group type: COMPARATOR
Intervention: Baseline condition of normal psychophysiologic function
Number of subjects: 26
Study 11493132 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic detailing (educational intervention)
Number of subjects: 17
Study 11493132 — intervention group
Group type: COMPARATOR
Intervention: Control (no academic detailing)
Number of subjects: 17
Study 9568750 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (patients with angina pectoris and significant stenosis)
Number of subjects: 964
Study 9568750 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (female patients)
Number of subjects: 964
Study 9568750 — intervention group
Group type: COMPARATOR
Intervention: Group 1
Number of subjects: 964
Study 9568750 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (male subgroup)
Number of subjects: 964
Study 9568750 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality during follow-up
Number of subjects: 964
Study 9568750 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein variables
Number of subjects: 964
Study 7924899 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 100 mg orally
Number of subjects: 20
Study 7924899 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg orally
Number of subjects: 20
Study 3413273 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AE) training for 12 weeks at 70% VO2max
Number of subjects: 36
Study 3413273 — intervention group
Group type: COMPARATOR
Intervention: Strength and flexibility (SF) training for 12 weeks with no aerobic exercise
Number of subjects: 36
Study 29552951 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure dilation (8 atm)
Number of subjects: 71
Study 29552951 — intervention group
Group type: COMPARATOR
Intervention: High-pressure dilation (30 atm)
Number of subjects: 71
Study 28488192 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) at 5 mg/kg
Number of subjects: 270
Study 28488192 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) at 100 mg/kg
Number of subjects: 270
Study 28488192 — intervention group
Group type: COMPARATOR
Intervention: Oxidized fish oil (OFO)
Number of subjects: 270
Study 28488192 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidized fish oil (OFO) + Green tea extract (GTE)
Number of subjects: 270
Study 25744160 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component school-based intervention
Number of subjects: 307
Study 23896011 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Number of subjects: 90
Study 23896011 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1 g
Number of subjects: 90
Study 23896011 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ibuprofen and acetaminophen
Number of subjects: 90
Study 23896011 — intervention group
Group type: COMPARATOR
Intervention: Rescue analgesics
Number of subjects: 90
Study 21726104 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (200 ‐ 300 mg/day)
Number of subjects: 80
Study 21726104 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine and Topiramate
Number of subjects: 80
Study 21726104 — intervention group
Group type: COMPARATOR
Intervention: Clozapine and Placebo
Number of subjects: 80
Study 21726104 — intervention group
Group type: COMPARATOR
Intervention: Clozapine and Topiramate vs Clozapine and Placebo
Number of subjects: 80
Study 17905957 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulation under anaesthesia
Number of subjects: 36
Study 17905957 — intervention group
Group type: COMPARATOR
Intervention: Hydrodilatation
Number of subjects: 36
Study 15276783 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg diazepam
Number of subjects: 84
Study 15276783 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 84
Study 15276783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 15276783 — intervention group
Group type: EXPERIMENTAL
Intervention: VRSCWT
Number of subjects: 84
Study 15276783 — intervention group
Group type: COMPARATOR
Intervention: Nonanxiogenic test
Number of subjects: 84
Study 11595119 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonates
Number of subjects: 3
Study 11595119 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 3
Study 9469684 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole, a new atypical antipsychotic, details on dosage and duration not available
Number of subjects: 0
Study 8031269 — intervention group
Group type: EXPERIMENTAL
Intervention: Zone I, stage 3 disease
Number of subjects: 2759
Study 8031269 — intervention group
Group type: EXPERIMENTAL
Intervention: Zone II, stage 3+ ROP involving nine to 12 sectors of 30 degrees
Number of subjects: 2759
Study 8031269 — intervention group
Group type: EXPERIMENTAL
Intervention: Zone II ROP without plus disease or zone III ROP
Number of subjects: 2759
Study 2656346 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (2 mg.kg‐1.day‐1)
Number of subjects: 49
Study 2656346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 2656346 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 49
Study 1219672 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine (PACaps)
Number of subjects: 0
Study 1219672 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 0
Study 1219672 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29747068 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with current romantic relationship stress (n=105)
Number of subjects: 190
Study 29747068 — intervention group
Group type: COMPARATOR
Intervention: Participants without current romantic relationship stress (n=85)
Number of subjects: 190
Study 28650922 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention practices
Number of subjects: 25
Study 28650922 — intervention group
Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 25
Study 26193865 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelve‐week resistance exercise program (3 times/week; 3 sets, 6‐8 repetitions at 75‐80% of the 1‐repetition maximum)
Number of subjects: 235
Study 24172548 — intervention group
Group type: EXPERIMENTAL
Intervention: Chilled saline irrigation
Number of subjects: 80
Study 24172548 — intervention group
Group type: COMPARATOR
Intervention: Room temperature saline irrigation
Number of subjects: 80
Study 21164373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventral fusion surgery
Number of subjects: 50
Study 21164373 — intervention group
Group type: COMPARATOR
Intervention: Dorsal fusion surgery
Number of subjects: 50
Study 19028329 — intervention group
Group type: COMPARATOR
Intervention: 0.25% atropine (0.25A)
Number of subjects: 71
Study 19028329 — intervention group
Group type: COMPARATOR
Intervention: 0.5% atropine (0.5A)
Number of subjects: 71
Study 19028329 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% atropine together with stimulation of the auricular acupoints (0.25A+E)
Number of subjects: 71
Study 16575721 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 243
Study 16575721 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 243
Study 15250227 — intervention group
Group type: COMPARATOR
Intervention: Conventional daytime CPAP titration
Number of subjects: 93
Study 15250227 — intervention group
Group type: COMPARATOR
Intervention: Manual daytime CPAP titration
Number of subjects: 93
Study 15250227 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic daytime CPAP titration (AutoSet)
Number of subjects: 93
Study 11162417 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose inhaled beclomethasone dipropionate (BDP) 500 microg t.i.d. plus salbutamol 200 microg t.i.d.
Number of subjects: 36
Study 11162417 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus salbutamol 200 microg t.i.d.
Number of subjects: 36
Study 9895266 — intervention group
Group type: EXPERIMENTAL
Intervention: High-effect base group
Number of subjects: 227
Study 9895266 — intervention group
Group type: COMPARATOR
Intervention: Low-effect group
Number of subjects: 227
Study 9895266 — intervention group
Group type: COMPARATOR
Intervention: High-effect apex group
Number of subjects: 227
Study 7993329 — intervention group
Group type: EXPERIMENTAL
Intervention: Worry
Number of subjects: 0
Study 7993329 — intervention group
Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 0
Study 7993329 — intervention group
Group type: COMPARATOR
Intervention: Present-oriented mentation
Number of subjects: 0
Study 2544132 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (substituted for digoxin)
Number of subjects: 20
Study 2544132 — intervention group
Group type: COMPARATOR
Intervention: Digoxin (continued treatment)
Number of subjects: 20
Study 1098764 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testolactone
Number of subjects: 110
Study 1098764 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fluorouracil alone
Number of subjects: 110
Study 1098764 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined androgen and antimetabolite therapy
Number of subjects: 110
Study 31980290 — intervention group
Group type: EXPERIMENTAL
Intervention: IV labetalol
Number of subjects: 0
Study 31980290 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nifedipine
Number of subjects: 0
Study 31980290 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 31200357 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 0
Study 31200357 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus best supportive care
Number of subjects: 0
Study 27167559 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocker shoes
Number of subjects: 16
Study 27028002 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant dextrin (10 g daily for 8 weeks)
Number of subjects: 55
Study 24075361 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% dextrose gel 200 mg/kg
Number of subjects: 237
Study 24075361 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 237
Study 21807139 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based therapy
Number of subjects: 11
Study 21807139 — intervention group
Group type: COMPARATOR
Intervention: Land-based therapy (active control group)
Number of subjects: 11
Study 20183539 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-guided slow-breathing (DGB)
Number of subjects: 0
Study 20183539 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous breathing (SB)
Number of subjects: 0
Study 16418664 — intervention group
Group type: EXPERIMENTAL
Intervention: Mersilene mesh‐wrapped hydroxyapatite (MHA) orbital implant
Number of subjects: 60
Study 16418664 — intervention group
Group type: COMPARATOR
Intervention: Sclera‐wrapped hydroxyapatite (SHA) orbital implant
Number of subjects: 60
Study 15459594 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/d
Number of subjects: 180
Study 15459594 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg/d
Number of subjects: 180